Lennox-Gastaut%2525252525252525252525252525252525252525252520syndrome

# Lennox-Gastaut Syndrome ## Overview Lennox-Gastaut Syndrome (LGS) is a severe, rare form of epilepsy characterized by multiple seizure types (tonic, atonic, absence, atypical absence), intellectual disability, and characteristic EEG patterns. Treatment aims to reduce seizure frequency and severity. ## Primary Indications Adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS). ## Adult Dosing * **Cannabidiol (CBD):** 2.5 mg/kg twice daily for the first week, then increased to 5 mg/kg twice daily for two weeks. Further titration can be done by increasing the dose by 2.5 mg/kg twice daily every week, up to a maximum of 20 mg/kg twice daily. * **Clobazam:** Initial dose typically 5 mg once or twice daily, titrate up to 20-30 mg per day, divided into two doses. May be increased further based on response and tolerability, with maximum doses potentially reaching 60 mg/day. * **Felbamate:** Initial dose 15 mg/kg/day divided into three doses. Increase every 2 weeks to a target dose of 45 mg/kg/day divided into three doses. * **Lamotrigine:** Patients naive to lamotrigine typically start with 25 mg daily. Titrate up every 2 weeks, increasing by 25 mg/day. Typical maintenance doses range from 100-400 mg/day, divided into two doses. * **Topiramate:** Initial dose 25-50 mg at bedtime. Increase by 25-50 mg every 2 weeks. Maintenance doses typically range from 100-400 mg/day, divided into two doses. Exact dosing and titration schedules are often guided by local protocols and individual patient response and tolerability. ## Pediatric Dosing * **Cannabidiol (CBD):** Dosing is the same as adult patients (2.5 mg/kg twice daily, titrating up to a maximum of 20 mg/kg twice daily). * **Clobazam:** Initial dose typically 0.25 mg/kg twice daily, titrate up to 0.5-1 mg/kg/day, divided into two doses. Maximum may reach 1-2 mg/kg/day or 60 mg/day, whichever is less. * **Felbamate:** Initial dose 15 mg/kg/day divided into three doses. Increase every 2 weeks to a target dose of 45 mg/kg/day divided into three doses. * **Lamotrigine:** Pediatric dosing is weight-based and depends on age. Standard titration schedules apply, but consult specific product labeling for precise pediatric dosing by age and weight. * **Topiramate:** Pediatric dosing is weight-based. Initial dose 0.5-1 mg/kg/day at bedtime. Increase by 0.5-1 mg/kg every 2 weeks. Maintenance doses typically range from 1-3 mg/kg/day, divided into two doses, up to a maximum of 5 mg/kg/day. ## Dose Adjustments * **Renal Impairment:** Dose reductions may be needed for drugs eliminated renally (e.g., topiramate, felbamate). Consult specific product information. * **Hepatic Impairment:** Dose reductions may be needed for drugs metabolized by the liver (e.g., CBD). Consult specific product information. * **Concomitant Medications:** Adjustments may be necessary due to drug interactions. ## Contraindications * Hypersensitivity to the specific agent. * Certain agents have contraindications related to specific medical conditions (e.g., hepatic impairment for felbamate). ## Adverse Effects Common adverse effects vary by agent but may include somnolence, fatigue, decreased appetite, diarrhea, nausea, vomiting, dizziness, ataxia, behavioral changes, and weight loss. Serious adverse effects include suicidal ideation, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), aplastic anemia and other hematologic abnormalities (felbamate), suicidal behavior and ideation (lamotrigine), and pharmacokinetic changes. ## Key Drug Interactions * **CYP450 Interactions:** Many antiepileptic drugs (AEDs) are inducers or inhibitors of CYP enzymes. This can affect the metabolism of other AEDs and non-antiepileptic medications. CBD is a moderate inhibitor of CYP2C19 and CYP2D6, and a weak inhibitor of CYP3A4 and CYP2C9. * **CNS Depressants:** Additive CNS depression with other sedating medications. ## Monitoring * **Seizure Frequency and Type:** Regular assessment of seizure control. * **Therapeutic Drug Levels:** For specific agents where correlation between blood levels and efficacy/toxicity is established. * **Complete Blood Counts (CBC):** Especially with felbamate, due to risk of aplastic anemia and agranulocytosis. * **Liver Function Tests (LFTs):** Especially with felbamate and CBD. * **Renal Function Tests:** Monitor with renally cleared agents. * **Electrolytes:** Particularly with topiramate (metabolic acidosis). * **Bone Mineral Density:** Consider with long-term use of certain AEDs. * **Suicidal Behavior and Ideation:** All patients treated with AEDs should be monitored for the emergence or worsening of depression, suicidal behavior, or any unusual changes in mood or behavior. ## Clinical Pearls * LGS management is complex and often requires a multidisciplinary approach with a neurologist. * Cross-titration of AEDs is common, with slow withdrawal of the old agent and slow introduction of the new agent to minimize seizure exacerbation and adverse effects. * Felbamate use is often limited due to serious risks (aplastic anemia, hepatic failure), and it is typically reserved for patients who have not responded to other treatments. * Vigabatrin is another option for LGS, particularly for infantile spasms that may evolve into LGS, but requires careful vision monitoring. * Response to treatment can be variable, and multiple agents may be needed. --- **Disclaimer:** This information is for educational purposes only and does not substitute for professional medical advice. Always consult with a qualified healthcare provider and refer to the most current prescribing information for any medication.